Prezista
NDC Package 53808-0672-1

11-digit billing NDC: 53808067201

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Prezista is co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-0672 and is authorized under FDA application NDA021976.

Identification & Billing

NDC Package Code
53808-0672-1
Package Description
30 TABLET, FILM COATED in 1 BLISTER PACK
Product Code
11-Digit Billing Format
53808067201
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Prezista
Dosage Form
-
Usage Information
Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in Table 2 [also see Drug Interactions (7.3), Table 7]. Table 2: Drugs That Are Contraindicated With PREZISTA/ritonavirDrug ClassDrugs Within Class That Are Contraindicated With PREZISTA/ritonavirClinical CommentAlpha 1-adrenoreceptor antagonistAlfuzosinPotential for serious and/or life-threatening reactions such as hypotension.Ergot DerivativesDihydroergotamine, Ergonovine, Ergotamine, MethylergonovinePotential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.GI Motility AgentCisapridePotential for serious and/or life-threatening reactions such as cardiac arrhythmias.NeurolepticPimozidePotential for serious and/or life-threatening reactions such as cardiac arrhythmias.Sedative/hypnoticsOrally administered Midazolam, TriazolamTriazolam and orally administered midazolam are extensively metabolized by CYP3A. Co-administration of triazolam or orally administered midazolam with PREZISTA/ritonavir may cause large increases in the concentrations of these benzodiazepines. Potential for serious and/or life-threatening events such as prolonged or increased sedation or respiratory depression.Herbal ProductsSt. John's Wort (Hypericum perforatum)Patients taking PREZISTA/ritonavir should not use products containing St. John's wort because co-administration may result in reduced plasma concentrations of darunavir. This may result in loss of therapeutic effect and development of resistance.HMG CoA Reductase InhibitorsLovastatin, SimvastatinPotential for serious reactions such as myopathy including rhabdomyolysis.For dosing recommendation regarding atorvastatin and pravastatin, see Table 7: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction.AntimycobacterialRifampinRifampin is a potent inducer of CYP450 metabolism. PREZISTA/ritonavir should not be used in combination with rifampin, as this may cause significant decreases in darunavir plasma concentrations. This may result in loss of therapeutic effect to PREZISTA.PDE-5 inhibitorSildenafil for treatment of pulmonary arterial hypertensionA safe and effective dose for the treatment of pulmonary arterial hypertension has not been established with PREZISTA/ritonavir. There is an increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope).Due to the need for co-administration of PREZISTA with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.

Regulatory & Marketing

Labeler Name
State Of Florida Doh Central Pharmacy
FDA Application #
NDA021976
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-01-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53808-0672-1 identifies a specific commercial package of 30 tablet, film coated in 1 blister pack of Prezista, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on July 01, 2009. The current certification is valid through December 31, 2017.

How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808067201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53808-0672-1
11-Digit CMS (5-4-2)
53808-0672-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.